More than half of respondents also perform exon 12 mutational testing in cases where V617F is negative, and more than half of respondents feel that JAK2 allele burden testing is important for correct MPN diagnosis, assessment of treatment, and disease prognosis. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.